Interventions for preventing silent cerebral infarcts in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Estcourt, Lise J ^a   Fortin, Patricia M ^a   Hopewell, Sally ^b   Trivella, Marialena ^b   Doree, Carolyn ^a   Abboud, Miguel R ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ARTICLE; BRAIN INFARCTION; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COGNITION; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKLE CELL ANEMIA; SILENT CEREBRAL INFARCTION; SYSTEMATIC REVIEW;

EID: 84990860322     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012389     Document Type: Article

References (56)

1. Abboud MR, Yim E, Mussallam KM, Adams RJ. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood 2011;118(4):894-8.
2. Adam S, Jonassaint J, Kruger H, Kail M, Orringer EP, Eckman JR, et al. Surgical and obstetric outcomes in adults with sickle cell disease. American Journal of Medicine 2008;121(10):916-21.
3. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine 1998;339(1):5-11.
4. Adekile AD, Yacoub F, Gupta R, Sinan T, Haider MZ, Habeeb Y, et al. Silent brain infarcts are rare in Kuwaiti children with sickle cell disease and high Hb F. Americal Journal of Hematology 2002;70(3):228-31.
5. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118(1):19-27.
6. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007;110(7):2749-56.
7. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011;117:1130-40; quiz 1436.
8. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Vasile M, Kasbi F, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood 2015;125(10):1653-61.
9. Casella JF, King AA, Barton B, White DA, Noetzel MJ, Ichord RN, et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatric Hematology & Oncology 2010;27(2):69-89.
10. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Archives of Disease in Childhood 2015;100(1):48-53.
11. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 1995;332(20):1317-22.
12. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology 2013;2013:439-46.
13. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Whesthoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122(6):1062-71.
14. DeBaun MR, Derdeyn CP, McKinstry RC 3rd. Etiology of strokes in children with sickle cell anemia. Mental Retardation & Developmental Disabilities Research Reviews 2006;12(3):192-9.
15. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012;119(20):4587-96.
16. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine 2014;371(8):699-710.
17. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood 2016;127(7):829-38.
18. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K, et al. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood 2012;120(19):3891-7.
20. Field JJ, Nathan DG. Advances in sickle cell therapies in the hydroxyurea era. Molecular Medicine 2014;20 Suppl 1:S37-42.
21. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. Journal of Clinical Investigation 2007;117(4):850-8.
22. Gravitz L, Pincock S. Sickle-cell disease. Nature 2014;515(7526):S1.
23. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine 2011;41(6 Suppl 4):S398-405.
24. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
25. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. Howard J. Transfusion therapy in sickle cell disease. 25th Regional Congress of the International Society of Blood Transfusion in Conjunction with the 33rd Annual Conference of the British Blood Transfusion Society; 2015 Jun 27 - Jul 01; London, United Kingdom. 2015.
29. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107(6):2279-85.
30. Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology 2006;81(7):503-10.
31. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration..
32. Marouf R, Gupta R, Haider MZ, Adekile AD. Silent brain infarcts in adult Kuwaiti sickle cell disease patients. American Journal of Hematology 2003;73(4):240-3.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA Statement. Annals of Internal Medicine 2009;151(4):264-9.
34. National Institute for Health and Care Excellence (NICE). Sickle cell disease. http://cks.nice.org.uk/sickle-cell-disease. UK: NICE, 2010; Vol. (accessed 10 April 2016).
35. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4]
36. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
37. Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG, et al. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Archives of Neurology 2001;58(12):2017-21.
38. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2012;381(9861):142-51.
39. Pleasants S. Epidemiology: a moving target. Nature 2014;515(7526):S2-3.
40. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. ASH Education Program Book 2013;1:447-56.
41. Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 2015;8(5):669-79.
42. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376(9757):2018-31.
43. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
44. Rumaney MB, Ngo Bitoungui VJ, Vorster AA, Ramesar R, Kengne AP, Ngogang J, et al. The co-inheritance of alpha-thalassemia and sickle cell anemia Is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS ONE 2014;9:e100516.
45. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. American Journal of the Medical Sciences 2010;339(3):266-9.
46. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology 2013;162(1):3-14.
49. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American Journal of Hematology 2012;87(8):795-803.
50. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
51. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; Vol. 8:16.
52. Ubesie A, Emodi I, Ikefuna A, Ilechukwu G, Ilechukwu G. Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research 2012;2(2):109-13.
53. van der Land V, Mutsaerts HJ, Engelen M, Heijboer H, Roest M, Hollestelle MJ, et al. Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. British Journal of Haematology 2016;172(2):274-84.
54. Venketasubramanian N, Prohovnik I, Hurlet A, Mohr JP, Piomelli S. Middle cerebral artery velocity changes during transfusion in sickle cell anemia. Stroke 1994;25(11):2153-8.
55. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biology of Blood and Marrow Transplantation 2010;16(2):263-72.
56. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663-72.